CN109810912A - One lactobacillus plantarum LH-511 and its application - Google Patents
One lactobacillus plantarum LH-511 and its application Download PDFInfo
- Publication number
- CN109810912A CN109810912A CN201711168190.8A CN201711168190A CN109810912A CN 109810912 A CN109810912 A CN 109810912A CN 201711168190 A CN201711168190 A CN 201711168190A CN 109810912 A CN109810912 A CN 109810912A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- drug
- food
- application
- blood glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 124
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 122
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 121
- 229940079593 drug Drugs 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 41
- 210000004369 blood Anatomy 0.000 claims abstract description 38
- 239000008280 blood Substances 0.000 claims abstract description 38
- 235000013305 food Nutrition 0.000 claims abstract description 38
- 239000008103 glucose Substances 0.000 claims abstract description 36
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 35
- 230000036541 health Effects 0.000 claims abstract description 17
- 235000013373 food additive Nutrition 0.000 claims abstract description 11
- 239000002778 food additive Substances 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 30
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
- 241000196324 Embryophyta Species 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 235000020124 milk-based beverage Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- -1 fatty acid ester Chemical class 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000012054 meals Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 35
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 16
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 13
- 210000000941 bile Anatomy 0.000 abstract description 5
- 235000013406 prebiotics Nutrition 0.000 abstract description 4
- 238000004321 preservation Methods 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 35
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- 239000006041 probiotic Substances 0.000 description 12
- 235000018291 probiotics Nutrition 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000031700 light absorption Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 229940099352 cholate Drugs 0.000 description 4
- 229960002227 clindamycin Drugs 0.000 description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 4
- 235000015140 cultured milk Nutrition 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229960001225 rifampicin Drugs 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 4
- 229960001082 trimethoprim Drugs 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000021107 fermented food Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004031 Carboxy-Lyases Human genes 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 2
- 241000726221 Gemma Species 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000004459 Nitroreductase Human genes 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 108020001162 nitroreductase Proteins 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000837 restrainer Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000345369 Edwardsiella hoshinae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186866 Lactobacillus thermophilus Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
This application discloses a lactobacillus plantarum LH-511 and its applications.The lactobacillus plantarum LH-511 of the application, deposit number are CGMCC No.14512.The lactobacillus plantarum LH-511 of the application, alpha-glucosidase activity inhibiting rate with higher can adjust blood glucose, have excellent prebiotic effect, also, have very strong acidproof and bile tolerance ability, being capable of long-term preservation；It can be used for preparing various food, health care product, food additives or the drugs for adjusting blood glucose, provide a kind of new efficient raw material to adjust blood glucose.
Description
Technical field
This application involves lactobacillus plantarum fields, more particularly to a lactobacillus plantarum LH-511 and its application.
Background technique
With the development of the social economy, the disease incidence of the metabolic syndromes such as diabetes and patient populations are in worldwide
In increasing trend year by year, it has also become endanger the third-largest chronic disease of human life and health.Diabetes are a kind of generations of multi-pathogenesis
Thanking property disease, clinical symptoms are hyperglycemia, glucose tolerance reduction and abnormal serum insulin concentration etc..Main cause is that pancreas is thin
Postprandial hyperglycemia caused by the insulin of intracrine is reduced or insulin sensitivity reduces, and hyperglycemia inhibits pancreatic secretion
Insulin reduces insulin and adjusts peripheral tissues to the absorbability of glucose, lacks so as to cause because of insulin secretion and effect
Fall into caused sugar, fat and protein metabolism disorder.
Diabetes are divided by the World Health Organization by the diabetes cause of disease and pathogenesis: the I type glycosuria of insulin-dependent
Disease, the type-2 diabetes mellitus of non-insulin-depending type, specific type and four seed type of gestational diabetes mellitus, wherein type 2 diabetes patient
Account for about 90% or more.Type-2 diabetes mellitus main feature shows as insulin resistance, i.e., cell can not be right after generating insulin self
It reacts, and can be with multiple complications, such as coronary heart disease, atherosclerosis, renal lesions, neuropathy, retina
Lesion and foot lesion etc. there is also typical " three-many-one-little " symptom, i.e., more drinks, diuresis, more foods and weight loss are existing
As.
Currently, there are mainly four types of the oral hypoglycemic drugs for the treatment of type-2 diabetes mellitus: (1) alpha-glucosidase (α-
Glucosidase) inhibitor: such as acarbose, voglibose；(2) Drugs Promoting Insulin Secretion: such as sulfonylurea, Rui Ge
How column are with Nateglinide etc.；(3) inhibit biguanides and the thiazolidinedione etc. of liver output glucose；(4) alleviate insulin to support
Anti- glitazone etc..Wherein, alpha-glucosidase restrainer can reversibly occupy the complexing position of alpha-glucosidase and sugar
Point inhibits alpha-glucosaccharase enzymatic polysaccharide to be degraded to monosaccharide, to delay the absorption of enteron aisle carbohydrate.Alpha-glucosaccharase
Enzyme inhibitor is the activity by inhibiting glucuroide, slows down the generation of glucose and absorption, reduces postprandial hyperglycemia, is adjusted
Whole blood glucose level improves the sensibility of insulin to reduce stimulation of the hyperglycemia to pancreas, effectively prevents and improve glycosuria
The generation of complications makes patient blood glucose maintain certain level, stabilizing blood sugar index.Alpha-glucosidase restrainer has effect
The advantages that mild lasting, nontoxic or Small side effects, by the concern of lot of domestic and international researcher, and its source also becomes and grinds
Study carefully bright spot.People are initially the glucosidase inhibitors extracted from actinomyces and chain enzyme bacteria, with going deep into for research, α-Portugal
The every field of ambient enviroment has been goed deep into the source of polyglycoside enzyme inhibitor.Wherein, the alpha-glucosidase suppression of originating in lactic acid bacterium
The important indicator that system is also screened at probiotics function of polysaccharide.Therefore, what screening acquisition was new there is high alpha-glucosidase to inhibit
The exploitation of the probiotics of effect, treatment and its novel drugs or health care product for type-2 diabetes mellitus is of great significance.
Summary of the invention
The purpose of the application is to provide one plant of new lactobacillus plantarum LH-511 and its application.
The application uses following technical scheme:
The one side of the application discloses a lactobacillus plantarum (Lactobacillus plantarum) LH-511,
Deposit number is CGMCC No.14512.
It should be noted that the deposit number of the application is the lactobacillus plantarum LH-511 of CGMCC No.14512, it is newly to send out
Existing one plant has the good bacterial strain for adjusting blood glucose function, and the research through the application confirms that the bacterial strain all has in vivo, in vitro
Have a good blood sugar decreasing effect, and have good tolerance to acid and bile, which means that the application lactobacillus plantarum
LH-511 can be eaten or take orally it is medicinal, to adjust blood glucose.Therefore, specially by the lactobacillus plantarum LH-511 of the application in
It is preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center, the address of depositary institution on August 10th, 2017
Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 Institute of Microorganism, Academia Sinica, deposit number are CGMCC No.14512, are protected
Hide entitled lactobacillus plantarum LH-511.
It should also be noted that, the lactobacillus plantarum LH-511 of the application is different from being in for existing other lactobacillus plantarums
In, the study found that the lactobacillus plantarum LH-511 of the application is greater than 33% to the external activity inhibiting rate of alpha-glucosidase, and
Lactic acid bacteria generally 10% once, have once in a while it is high be also no more than 20%, this explains the lactobacillus plantarum of application from principle
The blood sugar decreasing effect of LH-511.
The lactobacillus plantarum LH-511 that the another side of the application discloses the application adjusts food, the health care of blood glucose in preparation
Application in product, food additives, drug or composition.
The another side of the application discloses a kind of composition, and the composition contains the lactobacillus plantarum LH-511 of the application.
The composition of the application refer in addition to food, health care product, food additives, drug it is other types of contain this
Edible or Pharmaceutical composition, the composition of the lactobacillus plantarum LH-511 of application can be used for adjusting blood glucose.
It should be noted that the lactobacillus plantarum LH-511 due to the application has good function of blood sugar reduction, and can
With edible, therefore, various food, health care product, food additives or drug can be made into completely, for adjust blood glucose or
Play health-care effect.
The another side of the application discloses a kind of food, the lactobacillus plantarum LH-511 in the food containing the application.
Preferably, also containing acceptable additive or auxiliary material in bromatology in the food.
It is furthermore preferred that the food of the application is lactic acid drink or soya-bean milk drink.
It should be noted that the lactobacillus plantarum LH-511 of the application can be made various as existing lactobacillus
Food, such as lactic acid drink, soya-bean milk drink etc., prepared food mainly plays health-care effect, therefore, to the plant cream in food
Bacillus LH-511 activity bacterium amount or intake are not specifically limited, can be according to actual state flexible choice in practical application.
The studies have shown that of the application daily intakes 1.0 × 109The active plant lactobacillus LH-511 of CFU unit, can be substantially reduced dynamic
Blood-sugar content in object blood, the active bacteria dosage can be used as food, health care product, food additives or drug reference dosage or
With reference to intake.
In addition it is also necessary to which explanation, the food of the application, are sensu lato esculents existing in any form
Product are not limited in lactic acid drink or soya-bean milk drink, such as can also be fermented food, and fermented food also includes animal feed
Deng.
The another side of the application discloses a kind of health care product, the lactobacillus plantarum LH- in the health care product containing the application
511。
It, therefore, can be with it should be noted that the lactobacillus plantarum LH-511 of the application has the function of good adjusting blood glucose
It is added in existing various health care products, it is made to have the good healthcare function for adjusting blood glucose, as long as other groups of health care product
Divide between lactobacillus plantarum LH-511 without mutually inhibition or adverse side effect.
The another side of the application discloses a kind of food additives, the plant cream bar in the food additives containing the application
Bacterium LH-511.
It should be noted that the lactobacillus plantarum LH-511 of the application can be matched with common food material.Example
Such as, cereal and potato, cereal include rice, face, coarse cereals, and potato includes potato, sweet potato etc.；Animal food, including meat, fowl,
Fish, milk, egg etc.；Beans and its product, including soybean and other dry beans；Vegetable and fruit class, including fresh beans, rhizome, leaf vegetables, eggplant
Fruit etc.；Pure thermal energy food, including vegetable and animals oils, starch, table sugar and drinks etc.；Therefore, the lactobacillus plantarum LH- of the application
511 can play the guarantor for adjusting blood glucose individually as directly eating in food additives or the various food materials of modulator addition
Strong effect.
The another side of the application discloses a kind of drug, the lactobacillus plantarum LH-511 in the drug containing the application.
Preferably, the drug of the application adjusts blood glucose and specifically includes the enzyme for inhibiting alpha-glucosidase for adjusting blood glucose
Activity in one day dosage of drug, contains at least 1.0 × 109The active plant lactobacillus LH-511 of CFU unit.
Preferably, medically acceptable carrier or auxiliary material are also contained in drug.
Preferably, carrier or auxiliary material be selected from glucose, lactose, sucrose, starch, mannitol, dextrin, fatty glyceride,
Polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, albumin, water and
At least one of normal saline solution.
It is appreciated that drug when specific preparation is made, usually requires addition carrier or auxiliary material, only load to be added
Without mutually inhibition or adverse side effect between body or auxiliary material and lactobacillus plantarum LH-511.
It is furthermore preferred that drug is in tablet, granule, powder, capsule, solution, suspending agent, emulsion and lyophilized preparation
At least one；
It is furthermore preferred that lactobacillus plantarum piece.
It is furthermore preferred that including lactobacillus plantarum LH-511, dietary fiber, D-sorbite, crystallite fibre in lactobacillus plantarum piece
Dimension element and magnesium stearate.
It include the lactic acid bacteria freeze drying of lactobacillus plantarum LH-511 in a kind of preferred embodiment of the application, in lactobacillus plantarum piece
20% parts by weight of powder, 60% parts by weight of dietary fiber, 10% parts by weight of D-sorbite, 5% parts by weight of microcrystalline cellulose and tristearin
Sour 5% parts by weight of magnesium, after being mixed uniformly, tablet is made in tabletting.
It should be noted that the drug of the application, due to the lactobacillus plantarum LH-511 containing the application, have
The good function of adjusting blood glucose；The drug of the application can be the various of the lactobacillus plantarum LH-511 of independent active ingredient
Preparation can also be used cooperatively with other active ingredients, as long as not influencing activity between each other.
It is appreciated that the application lactobacillus plantarum LH-511 as active bacteria drug, as long as not influencing its strain activity,
Drug can use existing various dosage forms.And in the drug of the application, it further can also include normal in drug or dosage form
Auxiliary material, such as stabilizer, wetting agent, emulsifier, adhesive, isotonic agent etc..
Lactobacillus plantarum LH-511 activity bacterial content or pharmaceutical quantities are not particularly limited in the drug of the application, practical
It, can be according to the health status flexible choice of administration object in.But the studies have shown that of the application daily intake 1.0 ×
109The active plant lactobacillus LH-511 of CFU unit, the blood-sugar content that can be substantially reduced in animal blood, this dosage can be made
It is referred to for lactobacillus plantarum LH-511 activity bacterial content in drug or dosage.
As long as the lactobacillus plantarum LH-511 of the application and other probiotics or prebiotic combination of materials are in use, each component
Between there is no inhibiting effect or adverse reaction, it will be understood that best situation is that can have function between each component
Complementary or facilitation, such as compound probiotic piece can be made in the lactobacillus plantarum LH-511 of the application, by with it is other
Probiotic combinations reach more preferable or more active function, such as in addition to adjusting blood glucose, with other probiotic combinations, may be used also
Adjust functions of intestines and stomach to play, improve the functions such as immunity, specifically, can depending on each component of compound probiotic piece,
It is not limited here.
The beneficial effects of the present application are as follows:
The lactobacillus plantarum LH-511 of the application, alpha-glucosidase activity inhibiting rate with higher can adjust blood
Sugar has excellent prebiotic effect, also, has very strong acidproof and bile tolerance ability, being capable of long-term preservation；It can be used for making
Standby various food, health care product, food additives or the drugs for adjusting blood glucose provides a kind of new efficient former material to adjust blood glucose
Material.
Detailed description of the invention
Fig. 1 is the lactobacillus plantarum LH-511 growth curve chart that anti-cholate is tested in vitro in the embodiment of the present application.
The lactobacillus plantarum LH-511 of the application, classification naming are lactobacillus plantarum Lactobacillus plantarum,
Preservation, depositary institution were carried out in China Committee for Culture Collection of Microorganisms's common micro-organisms center on 08 10th, 2017
Address be Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 Institute of Microorganism, Academia Sinica, deposit number CGMCC
No.14512。
Specific embodiment
The lactobacillus plantarum LH-511 of the application is the activity with well-tuned blood glucose function of one plant of new separation discovery
Bacterium.The lactobacillus plantarum LH-511 of the application is in spherical bacillus form, diameter about 1 in MRS culture medium under an optical microscope
μm, no gemma, cell wall structures are complete；Without plasmid, metabolin does not generate the noxious materials such as D-ALPHA-Hydroxypropionic acid, indoles, does not express nitro
Reductase does not have the ability of generation amine yet；Gentamicin,Kanamycin,Streptomycin,Tetracycline,
Erythromycin、Clindamycin、Chloramphenicol、Amplicilin、Neomycin、Trimethoprim、
The minimal inhibitory concentration of 13 kinds of antibiotic such as Ciprofoxacin, Rifampicin, Vancomycin also all meets European Food
The regulation of drug surveilance office (abbreviation EFSA).
The lactobacillus plantarum LH-511 bacterial strain of the application is good to the resistance of simulation simulated gastric fluid environment, and external, internal
Alpha-glucosidase activity inhibiting rate all with higher, blood sugar decreasing effect are obvious；As it can be seen that the application newly separates the plant of discovery
Lactobacillus LH-511 has the necessary condition as medicinal fungus or edible mushroom, can be used in developing new drug, food, health care product, food
Product additive or other edible or Pharmaceutical compositions.
The application is described in further detail below by specific embodiment.Following embodiment only to the application carry out into
One step explanation, should not be construed as the limitation to the application.
Embodiment one
This example is sample as research object using traditional fermented food, therefrom the doubtful bacterium colony of separation screening lactic acid bacteria, then
It is identified using doubtful bacterial strain of the 16s DNA cloning to picking.It is as follows in detail:
(1) culture medium prescription
This example has prepared the MRS solid medium and MRS culture solution of optimization.
MRS solid medium, abbreviation MRS culture medium, the formula of 1L are as follows: casein peptone 10.0g/L, beef extract 10.0g/
L, yeast extract 5.0g/L, glucose 20.0g/L, dipotassium hydrogen phosphate 2.0g/L, Tween 80 1.0g/L, Triammonium citrate 2.0g/
L, sodium acetate 5.0g/L, magnesium sulfate 0.1g/L, manganese sulfate 0.05g/L, agar 17.5g.
MRS broth bouillon, the i.e. formula of MRS culture solution do not add agar only compared with MRS culture medium, remaining is identical.
The culture medium and culture solution of configuration adjust pH to 6.5, and 121 DEG C of sterilizing 20min, then 4 DEG C of refrigerations are spare.
(2) source of lactobacillus plantarum LH-511 bacterial strain and identification
Using Inner Mongol farmers' Yoghourt fermentation food as sample, 10 times of gradient dilutions are carried out with sterile saline, by sample
It is diluted to 10-3, it is coated on the MRS media surface of this example preparation, is placed in 37 DEG C of incubators and cultivates 24-48h, observes bacterium
Fall morphological feature.Therefrom the doubtful lactic acid bacteria of picking but bacterium colony scribing line separation on new MRS culture medium, 37 DEG C are incubated overnight
Afterwards, scribing line is carried out again to isolate and purify.Using sterile toothpick from several single colonies of picking on the second isolated culture medium of scribing line,
It is numbered respectively.It chooses wherein 20 plants of single colonies and carries out 16s DNA sequencing.
The primer sequence of this example 16s DNA cloning sequence as shown in SEQ ID NO.1 and SEQ ID NO.2.
SEQ ID NO.1:5 '-AGAGTTTGATCATGGCTCAG-3 '
SEQ ID NO.2:5 '-TAGGGTTACCTTGTTACGACTT-3 '
Primer is synthesized by BGI-Shenzhen.
PCR reaction system be include: 1 μ L of 10mM dNTPs, 10 × buffer, 5 μ L, 10mM in the reaction solution of 50 μ L
The 1 μ L of Taq enzyme of each 1 μ L of upstream and downstream primer, 1 μ L of bacterium solution pcr template, 5U/ μ L supplement ddH2O is supplemented to 50 μ L.
PCR reaction condition are as follows: 94 DEG C of initial denaturation 5min are recycled: 94 DEG C of 30s, 60 DEG C of 30s, 72 DEG C subsequently into 35
1min, after circulation terminates, 72 DEG C of extension 5min, 4 DEG C standby.
Gel extraction is carried out to pcr amplification product, and the PCR product of recycling is sequenced.This example uses kit
TaKaRa MiniBEST agarose GeL DNA Extraction kit carries out gel extraction, and detailed step is referring to kit
Specification.The PCR product of this example is sequenced by BGI-Shenzhen.
Sequencing result shows that the bacterial strain that number is LH-511,16s rDNA sequencing result is sequence shown in SEQ ID NO.3
Column.
SEQ ID NO.3:
5’-GAGGGCGCAGCTATACATGCAGTCGAACGAACTTCCGTTAATTGATTATGACGTACTTGTACTGAT
TGAGATTTTAACACGAAGTGAGTGGCGAACGGGTGAGTAACACGTGGGTAACCTGCCCAGAAGTAGGGGATAACACC
TGGAAACAGATGCTAATACCGTATAACAGAGAAAACCGCATGGTTTTCTTTTAAAAGATGGCTCTGCTATCACTTCT
GGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAAAGGCTCACCAAGGCAGTGATACGTAGCCGACCTGAGAGG
GTAATCGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGAC
GCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCTGTTGTTAAAGAAGAACGTG
GGTAAGAGTAACTGTTTACCCAGTGACGGTATTTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAA
TACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTCTTTTAAGTCTAATGTGAAAG
CCTTCGGCTCAACCGAAGAAGTGCATTGGAAACTGGGAGACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTA
GCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGCAACTGACGCTGAGGCTC
GAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGATTACTAAGTGTTGGAGGGT
TTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGTAATCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAAG
AATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGA
CATCTTCTGACAGTCTAAGAGATTAGAGGTTCCCTTCGGGGACAGAATGACAGTGTGCATGATGTCGTCAGCTCGTG
TCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTAT-3’
It is compared in ncbi database with BLAST tool, comparison result is shown, LH-511 bacterial strain and lactobacillus plantarum
Lactobacillus plantarum affiliation is nearest, and similitude reaches 99%, therefore, identifies that LH-511 bacterial strain is plant
Lactobacillus is named as lactobacillus plantarum LH-511, the i.e. lactobacillus plantarum of this example screening acquisition.
The single colonie of lactobacillus plantarum LH-511 is transferred in MRS culture solution and carries out pure culture, 37 DEG C of culture 18h, with
Standby subsequent use.
In addition, in MRS culture medium under optical microscopy observation of plant lactobacillus LH-511, the results show that plant is newborn
Bacillus LH-511 meets the form knot of lactobacillus plantarum in spherical bacillus form, about 1 μm of diameter, complete without gemma, cell wall structures
Structure.
The lactobacillus plantarum LH-511 that this example screening obtains was preserved in Chinese microorganism strain on 08 10th, 2017
Preservation administration committee common micro-organisms center, the address of depositary institution are Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 China
Institute of microbiology, the academy of sciences, deposit number are CGMCC No.14512.
(3) bacterium safety
1) antibiotics sensitivity is tested
This example test lactobacillus plantarum LH-511 to Gentamicin, Kanamycin, Streptomycin,
Tetracycline、Erythromycin、Clindamycin、Chloramphenicol、Amplicilin、Neomycin、
The resistance of 13 kinds of antibiotic such as Trimethoprim, Ciprofoxacin, Rifampicin, Vancomycin.Specific test side
Method is as follows:
13 kinds of antibiotic are first made into a series of 2 doubling dilution respectively, having respectively obtained concentration is 64 μ g/mL, 32 μ g/
The diluent of mL, 16 μ g/mL, 8 μ g/mL, 4 μ g/mL, 2 μ g/mL, 1 μ g/mL, 0.5 μ g/mL, 0.25 μ g/mL, 0.125 μ g/mL
Object.
Diluted antibiotic is separately added into 96 orifice plate corresponding apertures, then corresponding aperture is added lactobacillus plantarum LH-511's
MRS culture solution, after mixing, 37 DEG C of culture 48h observe cultivation results.This example is with the antibacterials minimal inhibitory concentration in each hole
(abbreviation MIC), characterizes the susceptibility of lactobacillus plantarum LH-511, test result is as shown in table 1.
1 lactobacillus plantarum LH-511 of table is to 13 kinds of antibiotic resistance measurement results
| Antibiotic | MIC(μg/mL) | EFSA provides safety value |
| Gentamicin | 2 | 16 |
| Kanamycin | 16 | 64 |
| Streptomycin | 16 | NR |
| Tetracycline | 8 | 32 |
| Erythromycin | 0.25 | 1 |
| Clindamycin | 0.25 | 2 |
| Chloramphenicol | 2 | 8 |
| Amplicilin | 0.125 | 2 |
| Neomycin | 0.5 | 8 |
| Trimethoprim | 64 | 128 |
| Ciprofoxacin | 16 | 64 |
| Rifampicin | 2 | 4 |
| Vancomycin | 8 | NR |
In table 1, NR indicate European Food drug surveilance office that is not required, table 1 the results show that this example separation obtain
Lactobacillus plantarum LH-511 to Gentamicin, Kanamycin, Tetracycline, Erythromycin,
Clindamycin、Chloramphenicol、Amplicilin、Neomycin、Trimethoprim、Ciprofoxacin、
The minimal inhibitory concentration of Rifampicin all meets the regulation of European Food drug surveilance office (abbreviation EFSA), and is much smaller than it
Defined safety value；Lactobacillus plantarum LH-511 is respectively 16 to the minimal inhibitory concentration of Streptomycin and Vancomycin
μ g/mL and 8 μ g/mL, although the two antibiotic do not require in EFSA, the value that this example measures is also all basic to be accorded with
It closes and is expected, it is seen then that the lactobacillus plantarum LH-511 of this example has preferable sensibility to antibiotic.
In addition, carrying out plasmid pumping using lactobacillus plantarum LH-511 of the small extraction reagent kit DP103 of TIANGEN plasmid to this example
It mentions, the results show that not finding that lactobacillus plantarum LH-511 carries any plasmid, shows lactobacillus plantarum LH-511 without gene level
Metastatic potential.
2) metabolin toxicity detection
The detection of lactic acid optical activity: it is detected using the D-/L- lactate acid detection kit of Irish Megazyme company.Knot
Fruit shows that the lactobacillus plantarum LH-511 of this example does not generate D-ALPHA-Hydroxypropionic acid.
Nitrate reductase activity detection: the lactobacillus plantarum LH-511 of this example of this example is transferred in MRS Liquid Culture
In base, for 24 hours in 37 DEG C of cultures, aseptically, activated bacterial strain is accessed in nitrate culture-medium by 3% bacterium amount that connects
After 37 DEG C of culture 5d, liquor kalii iodide and each 10 drop of starch solution, observation experiment result is added dropwise.Positive control test is done simultaneously.
Experimental result shows that bacterium solution does not become blue, is negative reaction, and positive control has change blue, illustrates the lactobacillus plantarum LH- of this example
511 do not express nitroreductase.
Indoles experiment: under aseptic condition, activated bacterial strain is linked into peptone water medium by 3% bacterium amount that connects
In, then 37 DEG C of culture 72h are added indole reagent 8~10 and drip, observation experiment result.Positive control test is done simultaneously.Experiment knot
Fruit shows that red annulus does not occur in bacterium solution, and positive control is displayed in red, and shows the lactobacillus plantarum LH-511 metabolism of this example
Edwardsiella hoshinae.
The detection of amino decarboxylase: the bacterium with amino acid decarboxylases, can decompose amino acid makes its decarboxylation generate amine
And carbon dioxide, so that culture medium is become alkalinity, such as lysine is decomposed into cadaverine, ornithine is decomposed into putrescine, and arginine decomposes
For spermine；Indicator, such as bromocresol purple is added dropwise, is feminine gender in yellow, it is purple for the positive.Therefore, this example is in aseptic condition
Under, activated bacterial strain is linked into peptone water medium, 37 DEG C of culture 72h by 3% bacterium amount that connects, bromine first is then added
Phenol violet 8~10 drips, observation experiment result.Titration results are in yellow, are feminine gender, illustrate that the lactobacillus plantarum LH-511 of this example does not have
The ability of standby generation amine.
Embodiment two
The lactobacillus plantarum LH-511 that this example obtains the separation of embodiment one has carried out external inhibition alpha-glucosidase enzyme
Test living.It is specific as follows:
It include: the PBS solution of 50 μ L concentration 0.1mol/L, pH=6.8 in the system of 205 μ L, 50 μ L concentration are 20mmol/
P-nitrophenol-α-D- pyrans Portugal glucoside (abbreviation PNPG, the be purchased from Sigma) solution of L and the sample to be tested of 25 μ L, will
Alpha-glucosaccharase enzyme solutions the reaction was continued the 20min of 30 μ L concentration 20U/mL is added in 37 DEG C of hatching 10min in mixture, then plus
Enter the Na that 50 μ L concentration are 1mol/L2CO3As reaction terminating liquid, reaction solution is surveyed into its light absorption value in 405nm, light absorption value with it is right
The free amount of nitrophenol PNP is directly proportional, and the PBS solution conduct that pH value is 0.1mol/L for 6.8 concentration is used in reaction system
The blank control of alpha-glucosaccharase enzyme solutions and sample to be tested calculates lactic acid bacteria and presses down to alpha-glucosidase enzyme activity after being reacted
Property processed, inhibiting rate calculation formula are thallus alpha-glucosidase enzyme activity inhibiting rate=[1- (A-B)/(C-D)] × 100%.
Wherein, A, B, C, D are respectively the light absorption value of four sample to be tested groups measurement, specifically, A is the extinction of positive group
Value, i.e. LH-511 containing lactobacillus plantarum phage solution and alpha-glucosaccharase enzyme solutions；B is to contain only lactobacillus plantarum LH-511
The light absorption value of the group measurement of phage solution；C is the light absorption value of control group, i.e., containing only alpha-glucosaccharase enzyme solutions；D is blank group
Light absorption value is also free of alpha-glucosaccharase enzyme solutions without lactobacillus plantarum LH-511 phage solution.
At the same time, this example measures it to phlorose using identical method using commercial strain 299V as control
The enzyme activity inhibiting rate of glycosides enzyme.
The results show that the alpha-glucosaccharase enzyme inhibition rate for the lactobacillus plantarum LH-511 that the separation of embodiment one obtains is
33.7%, inhibiting rate is very significant, and compareing commercial strain 299V is only 14.2%.As it can be seen that the plant that the separation of embodiment one obtains
Object lactobacillus LH-511 has good alpha-glucosidase activity inhibiting rate.
Embodiment three
This example tries external acidproof, the resistance to bile ability for the lactobacillus plantarum LH-511 that the separation of embodiment one obtains
It tests, specific as follows:
Simulate the gastric juice SGF:2.0g NaCl, 3.2g pepsin are prepared, the dense HCl of 7mL adds water to adjust to PH3.0, then
After 0.2 μm of filtering with microporous membrane, that is, the SGF liquid of this example is obtained, for use.
Picking lactobacillus plantarum LH-511 slant strains are in MRS culture solution, 37 DEG C of 16~18h of culture.Bacteria suspension 4
000r/min is centrifuged 15min, removes supernatant, weighs thallus weight in wet base, according to 0.1g/mL ratio again suspension thalline in physiological saline
In, it is added in SGF liquid according still further to the ratio of 1:10, mixes well to be placed in 37 DEG C of constant incubators and cultivate 2h, it is right respectively
It cultivates 0h and 2h and carries out cell count.Cell counts are as shown in table 2.
Tolerance count plate result of the 2 lactobacillus plantarum LH-511 of table to simulated gastric fluid SGF
| Bacterial strain | 0h is counted | 2h is counted | Survival rate |
| LH-511 | 2.56×109 | 2.55×109 | 99.6% |
Table 2 the results show that the lactobacillus plantarum LH-511 of embodiment one, viable count is maintained at a quantity after cultivating 2h
Grade, survival rate are up to 99.6%, and showing lactobacillus plantarum LH-511 in vitro has stronger acid-fast ability.
Further, the 10mL containing 0.3% cholate of the parts by weight bacterium solution of activation twice to be sterilized by the access of 1% amount
MRS culture solution is cultivated, and measures growth curve of the lactobacillus plantarum LH-511 in culture solution, and this example is repeated 4
Secondary test, as a result as shown in Figure 1.In Fig. 1, each curve is 4 duplicate growth curves respectively, the results show that in the training of cholate
Support base in lactobacillus plantarum LH-511 can normal growth, it is stronger to illustrate that the lactobacillus plantarum LH-511 of embodiment one has in vitro
Anti- bile ability.
Example IV
The lactobacillus plantarum LH-511 that this example obtains the separation of embodiment one adjusts cell factor experiment in vitro, specifically such as
Under:
Take growth conditions good, culture medium, waste liquid are drawn in the Human THP-1 cells system cell in logarithmic growth phase, centrifugation
It discards, appropriate complete medium is added, the cell for mixing removing is blown and beaten with pipettor, is prepared into cell suspension, cell count tune
Whole density is 5 × 105Cfu/mL draws on 0.9mL cell suspension inoculation to 24 orifice plates, above-mentioned spare bacteria suspension is drawn after 2h
It is added in corresponding aperture, makes the concentration 10 of lactic acid bacteria suspension in each hole6Cfu/mL concentration, three repetitions after culture for 24 hours, are inhaled
Supernatant is taken, 3000r/min is centrifuged 10min, takes supernatant, and test into ELISA: Interleukin -1β (IL-1 β), IL-6, tumour are bad
Necrosis factor-α (TNF-α) and IL-10, experimental result is as shown in table 3, wherein each group P < 0.05.
The cell in vitro cytokine regulatory test result of 3 lactobacillus plantarum LH-511 of table
| Group | IL-1β/(ng/mL) | IL-6/(ng/mL) | TNF-α(pg/mL) | IL-10/(ng/mL) |
| Blank control | 40.15 | 89.28 | 15.68 | 19.29 |
| LH-511 | 35.31 | 61.54 | 12.93 | 96.56 |
Table 3 the results show that the lactobacillus plantarum LH-511 of embodiment one to IL-1 β of THP-1 cell line, IL-6,
The proinflammatory factors such as TNF-α have downward effect, have up-regulation effect to anti-inflammatory factors such as IL-10, show lactobacillus plantarum LH-
511 have the function of anti-inflammatory really.
Embodiment five
The lactobacillus plantarum LH-511 that this example obtains the separation of embodiment one carries out internal study on the efficiency, and this example uses
5 week old rat of Sprague-Dawley system carries out in vivo studies, specific as follows:
1. the preparation of experimental strain
Activation lactobacillus plantarum LH-511 twice is inoculated in MRS fluid nutrient medium, in 37 DEG C of culture 18h,
6000r/m is centrifuged 10min, collects thallus after being washed with sterile saline.Then, 0.85% physiological saline is added, adjusts bacterium
Body number is to 1.0 × 109Then viable bacteria is sub-packed in 15mL centrifuge tube by daily usage amount by CFU/mL, taking dose is daily
2mL/ only, every group 10,6 groups, is fed 28 days totally.
2. experimental animal grouping and feeding manner
This example uses 5 week old rat of Sprague-Dawley system, induces SD system 5 using streptozotocin joint high lipid food
Week old rat completes hyperglycemic rat modeling, feeds to the 28th day, is equally divided into 6 groups, every group 10.Each group is respectively according to such as
Under type continues to feed:
Model group, the group feed high-calorie feed and distilled water；
Positive group, which feeds high-calorie feed and melbine, and melbine is supplied by 0.3mg/g weight；
LH-511 group, the group feed high-calorie feed and lactobacillus plantarum LH-511；
299v group, the group feed high-calorie feed and probiotics 299v；
Sc52 group, the group feed high-calorie feed and probiotics Sc52；
Normal group, this group of feeding standard feed and distilled water.
The above forage feed amount is identical, distilled water, melbine, lactobacillus plantarum LH-511, probiotics 299v and prebiotic
Bacterium Sc52 daily every 2mL stomach-filling in each group, continues 28 days.
Wherein, high-calorie feed is voluntarily prepared, and is that fat or high-fat object are added on the basis of the standard feed of purchase
Matter, specific formula are as follows: 78.8% standard feed, 10% lard, 10% yolk powder, l% cholesterol, 0.2% cholate.Standard feed
It speeds the muroid special feed of experimental animal feed factory to purchase in Henan day.Probiotics 299v is commercial strain, commercially available purchase；
Probiotics Sc52 is purchased from CGMCC, and deposit number CGMCCNo.11027 is recorded in patent CN 201510581420.8.
3. sample acquisition is tested with analysis
Before formal test and blood was collected the 28th day period.Blood-sampling method is after going on a hunger strike a night, to adopt in rat femoral vein
Blood, 4000r/m is centrifuged 10min and separates serum after blood coagulation.Detect fasting blood-glucose, 2h-plasma glucose, glycosylated hemoglobin, adiponectin
With the content of TNF-α and the 28th day measurement hepatic tissue SOD value.
4. experimental result
Experimental result is as shown in table 4, wherein each group P < 0.05.
4 animal test results of table
Table 4 the results show that the 28th day empty stomach blood glucose target of LH-511 group rat oral gavage is reduced than model group
The 28th day postprandial blood sugar index of 24.0%, LH-511 group reduces 37.1% than model group, shows that lactobacillus plantarum LH-511 has
There is internal antidiabetic function, and other indexs show lactobacillus plantarum LH-511 to internal inflammatory environment caused by hyperglycemia
Also there is relaxation effect.Also, the lactobacillus plantarum LH-511 of this example, function and other control strain 299v (P > 0.05) and
Sc52 (12.6%, P < 0.05) is more preferable compared to effect.
Embodiment six
Respectively common drug and food is made in the lactobacillus plantarum LH-511 that the separation of embodiment one obtains by this example, specifically
It is as follows:
(1) lactobacillus plantarum tablet
Formula: CFU109The freeze-dried powder 20% of lactobacillus plantarum LH-511, dietary fiber 60%, D-sorbite 10%,
Microcrystalline cellulose 5%, magnesium stearate 5%；The above component is parts by weight, and after mixing by each component, tablet is made in tabletting.
Wherein, the freeze-dried powder of lactobacillus plantarum LH-511 is that its bacteria suspension is freezed vacuum drying in an aseptic environment using freeze dryer
It forms.
(2) lactobacillus plantarum fermentation cultured milk
Milk powder and water are mixed, homogeneous, sterilized with 121 DEG C of ultra-high temperature sterilization 300s, is cooled to 42 DEG C, access activation
Good leavening: access amount is parts by weight 0.4% in total for lactobacillus bulgaricus and lactobacillus thermophilus bacterium powder.It ferments at 42 DEG C
10h, it is 10 that parts by weight 1%CFU is added after cooling8Lactobacillus plantarum LH-511, stirring, it is filling.
Wherein, milk powder is conventional use of milk powder in Yoghourt preparation.
(3) pharmacodynamic test of the above drug and food
This example is using the identical method of embodiment five to the sour ox of lactobacillus plantarum tablet and lactobacillus plantarum fermentation of this example
Cream carries out hypoglycemic test in vivo.
Wherein, suspension made of sterile water, adjustment bacterium number to 1.0 × 10 are added after lactobacillus plantarum tablet is smashed to pieces9CFU/mL。
Lactobacillus plantarum fermentation cultured milk equally adds suspension made of sterile water, adjustment bacterium number to 1.0 × 109CFU/mL.It is replaced with this
Viable bacteria suspension in embodiment five.
Feeding method and subsequent blood sampling, measurement method are all identical as embodiment five.
The results show that drawing blood after being fed high lipid food rat 28 days with the drug of lactobacillus plantarum LH-511 and food respectively
The rat of lactobacillus plantarum fermentation cultured milk is fed in detection, discovery, its blood glucose has dropped 24.5%, P < 0.05 compared with the 0th day,
0th day fasting plasma glucose concentration is 4.7mmol/L, and the fasting plasma glucose concentration after 28 days is 3.55mmol/L；Feed plant cream bar
The rat of bacterium piece is suitable with the lactobacillus plantarum fermentation rat effect of cultured milk is fed, and the fasting plasma glucose concentration after 28 days has dropped
About 24.8%, P < 0.05.As it can be seen that the drug and food of addition lactobacillus plantarum LH-511, lactobacillus plantarum LH-511 is big
It is colonized in mouse body and has played effect, show that the drug for adding lactobacillus plantarum LH-511 and truly having for food reduce blood glucose in vivo
The effect of.
The foregoing is a further detailed description of the present application in conjunction with specific implementation manners, and it cannot be said that this Shen
Specific implementation please is only limited to these instructions.For those of ordinary skill in the art to which this application belongs, it is not taking off
Under the premise of from the application design, a number of simple deductions or replacements can also be made.
SEQUENCE LISTING
<110>Shenzhen Hua Da three lives garden Science and Technology Ltd.
<120>one lactobacillus plantarum LH-511 and its application
<130> 17I25288
<160> 3
<170> PatentIn version 3.3
<210> 1
<211> 20
<212> DNA
<213>artificial sequence
<400> 1
agagtttgat catggctcag 20
<210> 2
<211> 22
<212> DNA
<213>artificial sequence
<400> 2
tagggttacc ttgttacgac tt 22
<210> 3
<211> 1110
<212> DNA
<213>the 16s rDNA sequencing result of lactobacillus plantarum LH-511
<400> 3
gagggcgcag ctatacatgc agtcgaacga acttccgtta attgattatg acgtacttgt 60
actgattgag attttaacac gaagtgagtg gcgaacgggt gagtaacacg tgggtaacct 120
gcccagaagt aggggataac acctggaaac agatgctaat accgtataac agagaaaacc 180
gcatggtttt cttttaaaag atggctctgc tatcacttct ggatggaccc gcggcgtatt 240
agctagttgg tgaggtaaag gctcaccaag gcagtgatac gtagccgacc tgagagggta 300
atcggccaca ttgggactga gacacggccc agactcctac gggaggcagc agtagggaat 360
cttccacaat ggacgcaagt ctgatggagc aacgccgcgt gagtgaagaa gggtttcggc 420
tcgtaaagct ctgttgttaa agaagaacgt gggtaagagt aactgtttac ccagtgacgg 480
tatttaacca gaaagccacg gctaactacg tgccagcagc cgcggtaata cgtaggtggc 540
aagcgttatc cggatttatt gggcgtaaag cgagcgcagg cggtctttta agtctaatgt 600
gaaagccttc ggctcaaccg aagaagtgca ttggaaactg ggagacttga gtgcagaaga 660
ggacagtgga actccatgtg tagcggtgaa atgcgtagat atatggaaga acaccagtgg 720
cgaaggcggc tgtctggtct gcaactgacg ctgaggctcg aaagcatggg tagcgaacag 780
gattagatac cctggtagtc catgccgtaa acgatgatta ctaagtgttg gagggtttcc 840
gcccttcagt gctgcagcta acgcattaag taatccgcct ggggagtacg accgcaaggt 900
tgaaactcaa aagaattgac gggggcccgc acaagcggtg gagcatgtgg tttaattcga 960
agctacgcga agaaccttac caggtcttga catcttctga cagtctaaga gattagaggt 1020
tcccttcggg gacagaatga cagtgtgcat gatgtcgtca gctcgtgtcg tgagatgttg 1080
ggttaagtcc cgcaacgagc gcaaccctat 1110
Claims (10)
1. a lactobacillus plantarum LH-511, deposit number is CGMCC No.14512.
2. lactobacillus plantarum LH-511 according to claim 1, it is characterised in that: the lactobacillus plantarum LH-511 is to α-Portugal
The maximum inhibition of polyglycoside enzyme is greater than 33%.
3. food, health care product, food that lactobacillus plantarum LH-511 according to claim 1 or 2 adjusts blood glucose in preparation
Application in additive, drug or composition.
4. a kind of composition, it is characterised in that: the composition contains lactobacillus plantarum LH-511 of any of claims 1 or 2.
Preferably, the composition can be used for adjusting blood glucose.
5. a kind of food, it is characterised in that: contain lactobacillus plantarum LH-511 of any of claims 1 or 2 in the food.
Preferably, also containing acceptable additive or auxiliary material in bromatology in the food；
Preferably, the food is lactic acid drink or soya-bean milk drink.
6. a kind of health care product, it is characterised in that: contain lactobacillus plantarum LH- of any of claims 1 or 2 in the health care product
511。
7. a kind of food additives, it is characterised in that: contain plant cream of any of claims 1 or 2 in the food additives
Bacillus LH-511.
8. a kind of drug, it is characterised in that: contain lactobacillus plantarum LH-511 of any of claims 1 or 2 in the drug.
9. drug according to claim 8, it is characterised in that: the drug is used to adjust blood glucose, the drug one day
In dosage, contain at least 1.0 × 109The active plant lactobacillus LH-511 of CFU unit.
10. drug according to claim 8 or claim 9, it is characterised in that: also contain medically acceptable load in the drug
Body or auxiliary material；
Preferably, the carrier or auxiliary material be selected from glucose, lactose, sucrose, starch, mannitol, dextrin, fatty glyceride,
Polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, albumin, water and
At least one of normal saline solution；
Preferably, the drug is in tablet, granule, powder, capsule, solution, suspending agent, emulsion and lyophilized preparation
It is at least one；
It is furthermore preferred that the drug is lactobacillus plantarum piece, it include lactobacillus plantarum LH-511, meals in the lactobacillus plantarum piece
Eat fiber, D-sorbite, microcrystalline cellulose and magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711168190.8A CN109810912B (en) | 2017-11-21 | 2017-11-21 | Lactobacillus plantarum LH-511 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711168190.8A CN109810912B (en) | 2017-11-21 | 2017-11-21 | Lactobacillus plantarum LH-511 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109810912A true CN109810912A (en) | 2019-05-28 |
| CN109810912B CN109810912B (en) | 2023-05-23 |
Family
ID=66600578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711168190.8A Active CN109810912B (en) | 2017-11-21 | 2017-11-21 | Lactobacillus plantarum LH-511 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109810912B (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110522035A (en) * | 2019-09-30 | 2019-12-03 | 中加健康工程研究院(合肥)有限公司 | A kind of humanized's probiotics and its application in terms of assisting in reducing blood sugar |
| CN111304134A (en) * | 2020-03-26 | 2020-06-19 | 上海理工大学 | Lactobacillus plantarum capable of effectively relieving diabetes |
| CN111387290A (en) * | 2020-03-03 | 2020-07-10 | 宁波大学 | A functional yogurt product with inhibiting α-glucosidase and tyrosinase activities and preparation method thereof |
| CN111733111A (en) * | 2020-07-20 | 2020-10-02 | 广东南芯医疗科技有限公司 | Lactobacillus plantarum NX-1 and application thereof in preparation of hypoglycemic drugs |
| CN112852657A (en) * | 2019-11-27 | 2021-05-28 | 大江生医股份有限公司 | Application of lactobacillus plantarum and/or metabolite thereof in preparing weight-losing composition |
| CN113234639A (en) * | 2021-06-16 | 2021-08-10 | 广东海天创新技术有限公司 | Lactobacillus plantarum ZF632 and application thereof |
| CN113462613A (en) * | 2021-08-03 | 2021-10-01 | 浙江大学 | Lactobacillus plantarum ZJUIDS04 capable of reducing blood sugar and application thereof |
| CN113881604A (en) * | 2021-11-10 | 2022-01-04 | 深圳大学 | Lactobacillus plantarum MM89 and polysaccharide and application thereof |
| CN114752529A (en) * | 2022-04-29 | 2022-07-15 | 科郦有限公司 | Lactobacillus plantarum HOM3201 strain and its live bacteria preparation, preparation method and use |
| CN115851500A (en) * | 2022-09-23 | 2023-03-28 | 四川大学 | Lactobacillus plantarum and application thereof |
| CN117042626A (en) * | 2020-09-21 | 2023-11-10 | 国民生物公司 | New lactic acid bacteria isolated from aged meat and their uses |
| CN120330077A (en) * | 2024-06-14 | 2025-07-18 | 艾地盟(上海)管理有限公司 | Lactobacillus plantarum JN-7, bacterial powder, preparation method, probiotic composition and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105132318A (en) * | 2015-09-01 | 2015-12-09 | 扬州大学 | Lactobacillus plantarum grx16 and application thereof |
-
2017
- 2017-11-21 CN CN201711168190.8A patent/CN109810912B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105132318A (en) * | 2015-09-01 | 2015-12-09 | 扬州大学 | Lactobacillus plantarum grx16 and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| H. MICHLMAYR ET AL.: "Isolation and basic characterization of a β-glucosidase from a strain of Lactobacillus brevis isolated from a malolactic starter culture", 《J APPL MICROBIOL》 * |
| 吕嘉枥等: "具有α－葡萄糖苷酶抑制性益生乳酸菌的筛选", 《陕西科技大学学报》 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110522035A (en) * | 2019-09-30 | 2019-12-03 | 中加健康工程研究院(合肥)有限公司 | A kind of humanized's probiotics and its application in terms of assisting in reducing blood sugar |
| CN112852657A (en) * | 2019-11-27 | 2021-05-28 | 大江生医股份有限公司 | Application of lactobacillus plantarum and/or metabolite thereof in preparing weight-losing composition |
| CN111387290A (en) * | 2020-03-03 | 2020-07-10 | 宁波大学 | A functional yogurt product with inhibiting α-glucosidase and tyrosinase activities and preparation method thereof |
| CN111387290B (en) * | 2020-03-03 | 2023-01-31 | 宁波大学 | A functional yogurt product with inhibitory activity of α-glucosidase and tyrosinase and its preparation method |
| CN111304134A (en) * | 2020-03-26 | 2020-06-19 | 上海理工大学 | Lactobacillus plantarum capable of effectively relieving diabetes |
| CN111733111B (en) * | 2020-07-20 | 2022-04-01 | 广东南芯医疗科技有限公司 | Lactobacillus plantarum NX-1 and application thereof in preparation of hypoglycemic drugs |
| CN111733111A (en) * | 2020-07-20 | 2020-10-02 | 广东南芯医疗科技有限公司 | Lactobacillus plantarum NX-1 and application thereof in preparation of hypoglycemic drugs |
| CN117042626A (en) * | 2020-09-21 | 2023-11-10 | 国民生物公司 | New lactic acid bacteria isolated from aged meat and their uses |
| CN113234639A (en) * | 2021-06-16 | 2021-08-10 | 广东海天创新技术有限公司 | Lactobacillus plantarum ZF632 and application thereof |
| CN113462613A (en) * | 2021-08-03 | 2021-10-01 | 浙江大学 | Lactobacillus plantarum ZJUIDS04 capable of reducing blood sugar and application thereof |
| CN113881604A (en) * | 2021-11-10 | 2022-01-04 | 深圳大学 | Lactobacillus plantarum MM89 and polysaccharide and application thereof |
| CN113881604B (en) * | 2021-11-10 | 2023-02-28 | 深圳大学 | Lactobacillus plantarum MM89 and polysaccharide and application thereof |
| CN114752529A (en) * | 2022-04-29 | 2022-07-15 | 科郦有限公司 | Lactobacillus plantarum HOM3201 strain and its live bacteria preparation, preparation method and use |
| CN114752529B (en) * | 2022-04-29 | 2023-12-19 | 科郦有限公司 | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof |
| CN115851500A (en) * | 2022-09-23 | 2023-03-28 | 四川大学 | Lactobacillus plantarum and application thereof |
| CN115851500B (en) * | 2022-09-23 | 2024-04-02 | 四川大学 | Lactobacillus plantarum and application thereof |
| CN120330077A (en) * | 2024-06-14 | 2025-07-18 | 艾地盟(上海)管理有限公司 | Lactobacillus plantarum JN-7, bacterial powder, preparation method, probiotic composition and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109810912B (en) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109810912A (en) | One lactobacillus plantarum LH-511 and its application | |
| CN109810913A (en) | One plant of Lactobacillus rhamnosus ASD-9 and its application | |
| CN102093967B (en) | A strain of Enterococcus faecium derived from mink and its application | |
| CN110122877B (en) | Lactobacillus rhamnosus and application thereof | |
| CN102533618B (en) | A kind of Lactobacillus plantarum CCFM8724 and its use | |
| CN109182207B (en) | Lactobacillus acidophilus La-SJLH001 with probiotic functions of regulating blood sugar level, cholesterol level and the like and application thereof | |
| CN113061543A (en) | Lactobacillus plantarum and application thereof | |
| CN107287133A (en) | One lactobacillus plantarum LLY 606 and its application | |
| CN108004155A (en) | Lactobacillus plantarum pc-26 bacterial strains and its application | |
| CN106883995A (en) | Pediococcus acidilactici JQII-5 bacterial strains and application thereof | |
| CN103966124A (en) | Compound microecological preparation and additive, as well as premix thereof | |
| CN116814501B (en) | Bifidobacterium longum subspecies capable of relieving obesity and application thereof | |
| CN114574406B (en) | Lactobacillus rhamnosus strain WKA55, and application and product thereof in preparation of product for preventing and treating alcoholic liver injury | |
| CN115094012B (en) | Preparation method and application of bacillus coagulans BC-HYC strain microbial inoculum | |
| CN106883997A (en) | Pediococcus pentosaceus JQI-7 bacterial strains and its application | |
| CN116746683B (en) | Animal Bifidobacterium lactis subspecies BAL-28 and its fermentation products, flora CW and application for preventing indigestion and flatulence and promoting absorption | |
| WO2017012571A1 (en) | Use of bacillus coagulans strain in increasing egg production in laying hen | |
| CN113337427A (en) | Lactobacillus plantarum HNU082, composition and application thereof | |
| CN117050914A (en) | Acremonium muciniphilum and application thereof in improving GLP-1 secretion | |
| CN110522035A (en) | A kind of humanized's probiotics and its application in terms of assisting in reducing blood sugar | |
| CN101139557A (en) | A kind of Lactobacillus casei and its application in improving blood lipid metabolism and immune regulation | |
| CN104830711B (en) | A kind of solid fermentation process of bacillus amyloliquefaciens feed addictive | |
| CN118652823B (en) | A strain of Weizmannella coagulans with anti-aging and antioxidant effects and its postbiotics and applications | |
| CN102093966B (en) | Mink Lactobacillus plantarum MDL1118 and its application | |
| CN105274032B (en) | A kind of antagonism campylobacter jejuni and the lactobacillus reuteri for inhibiting its flaA gene expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200113 Address after: 518120 A205, Peng Fei Road, Dapeng street, Dapeng New District, Shenzhen, Guangdong, China, 7 Applicant after: Shenzhen Huada Gene Agriculture Holding Co.,Ltd. Applicant after: BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO.,LTD. Address before: 518057 4 3-B, 28 North District, Langshan Road, Xili street, Nanshan District, Shenzhen, Guangdong. Applicant before: BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO.,LTD. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |